Moreover, combining EV-PH20 with anti-PD-L1 antibody provides potent tumor-specific CD8+ T cell immune responses as well as prominent tumor growth inhibition both in syngeneic and spontaneous breast cancer models [207]. Here, CD8A is linked to breast carcinoma.